Cost-effectiveness of microscopy of urethral smears for asymptomatic Mycoplasma genitalium urethritis in men in England by Sutton, Andrew J. et al.
Cost-effectiveness of microscopy of urethral smears for asymptomatic Mycoplasma
genitalium urethritis in men in England
Sutton, Andrew J.; Roberts, Tracy E.; Jackson, Louise; White, Peter J.; Birger, Ruthie;
Estcourt, Claudia; Saunders, John
Published in:







Link to publication in ResearchOnline
Citation for published version (Harvard):
Sutton, AJ, Roberts, TE, Jackson, L, White, PJ, Birger, R, Estcourt, C & Saunders, J 2018, 'Cost-effectiveness
of microscopy of urethral smears for asymptomatic Mycoplasma genitalium urethritis in men in England',
International Journal of STD and AIDS, vol. 29, no. 1, pp. 72-79. https://doi.org/10.1177/0956462417717651
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please view our takedown policy at https://edshare.gcu.ac.uk/id/eprint/5179 for details
of how to contact us.
Download date: 29. Apr. 2020
 Page 1 of 16 
 
Introduction 
Over the past decade, there has been a change in the clinical investigation and management of 
men attending sexual health services in the UK. Previously, all men, regardless of symptoms, 
underwent urethral smears, a process by which a sample is taken from inside the urethra and 
Gram stained for examination by light microscopy (1). This allowed for the immed ia te 
diagnosis of two conditions: presumptive gonorrhoea and non-gonococcal urethrit is 
(inflammation of the urethra in the absence of gonorrhoea). Men with either of these conditions, 
and their sexual partners, were then offered immediate treatment with appropriate antibiot ics 
whilst waiting several days for more definitive results.  
With the widespread use of sensitive and specific, non-invasive urine testing for chlamydia and 
gonorrhoea, and growing financial pressures on services, guidelines now recommend only 
performing urethral microscopy in symptomatic men (1). A consequence of this change in 
practice is that asymptomatic men with urethritis, caused by neither chlamydia nor gonorrhoea 
(known as non-chlamydial, non-gonococcal urethritis or NCNGU), no longer receive empirica l 
antimicrobial therapy. Their sexual partners are also left untreated. However, at the time of the 
most recent national audit (1), a small number of clinics continued to provide routine urethral 
microscopy to asymptomatic men, contrary to the guidelines.  
The potential impact of this change in practice on costs and patients outcomes is not clear and 
has not yet been explored in any depth. Asymptomatic urethritis has many causes, both 
infectious and non-infectious (1). Notably, Mycoplasma genitalium is present in 8-10% of men 
with asymptomatic urethritis (1) and is associated with both cervicitis and pelvic inflammatory 
disease in women (2). There is limited access to testing for M. genitalium in the UK and few 
men are tested for this organism. Therefore, whereas previously, men with asymptomatic 
urethritis secondary to M. genitalium and their partners may have received successful treatment 
as part of empirical therapy for urethritis, this is no longer the case.   
The focus of this study is on the potential cost implications of this change in clinical practice 
assuming that some men with asymptomatic NCNGU have M. genitalium, which can have 
adverse and costly reproductive health outcomes in their female sexual partners. Specifica lly, 
the objective of this economic evaluation is to determine whether the screening landscape at 
the time of the last national audit, in which a small number of clinics continued to perform 
routine microscopy in asymptomatic men is a cost-effective approach to diagnosing and 
treating asymptomatic NCNGU compared to the national guideline recommending not 
performing microscopy for this patient group.   
Methods 
In order to estimate the impact of testing and treatment on the future transmission of possible 
significant pathogens responsible for asymptomatic NCNGU it is necessary to use an 
appropriate modelling approach for infectious diseases which can describe the transmission of 
M genitalium between individuals, namely a transmission dynamic model (TDM) (3, 4). In this 
study a TDM describing the transmission of M genitalium in the population of 16-30 year olds 
in England was constructed in order to examine changes in the use of urethral microscopy in 
asymptomatic men in GUM clinics. This economic evaluation uses outputs from this model, 
along with secondary data describing resource use and takes the form of a cost-effectiveness 
analysis carried out from a health care provider perspective, with costs valued at 2014/2015 
UK prices. 
Model structure 
The output used in this economic analysis is taken from a TDM which has been described in 
full elsewhere (5). In brief, this is a compartmental transmission model of the natural history 
of M genitalium, its diagnosis, and treatment levels, and thus only M genitalium was considered 
in this cost-effectiveness analysis. Heterogeneous sexual behaviour is described in the model 
which was parameterised by behaviour data from a number of key UK surveys, nationa l 
surveillance data, and with the natural history of NCNGU being informed from data in the 
literature. The model describes the incidence and prevalence of symptomatic and asymptomatic 
infection, PID, care-seeking behaviour due to symptoms, partner notification, and the 
possibility of treatment failure. The uncertainty of the parameters in the model was also 
factored into the model parameterisation.  
The time horizon for the economic analysis is 20 years, although this is subject to sensitivity 
analysis. It was felt that a time horizon longer than this would not be appropriate due to the 
inevitable changes to testing technology and approaches to offering STI screening to the 
population in the future. A discount rate of 3.5% was applied to costs and outcomes in 
accordance with NICE guidelines (6). 
All settings where sexual health services are provided were initially considered for inclus ion 
in this analysis. However, guidelines detailing the specific pathways and resources used at 
different sexual health service settings were sparse with the most reliable clinical data and cost 
data found in the literature being related to GP and GUM settings, with GP consultations being 
considered due to the possibility of referral onwards to GUM services for further management. 
In this study the methodological focus is narrowed to the diagnosis and treatment of NCNGU 
in general practice and GUM clinics. 
Testing Pathways for Economic analysis 
Three different pathways are compared in terms of their resource use and costs, each 
representing alternative approaches to the testing and treatment of patients with asymptomatic 
NCNGU. These pathways represent: 1) the current recommended practice of not offering 
microscopy to asymptomatic men in GUM settings; 2) offering a small proportion (5%) of 
asymptomatic men microscopy (i.e. men attending a small number of GUM services) ; and 3) 
offering microscopy to all asymptomatic men attending all GUM services. These three 
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100% Symptomatic and 5% of 





All patients on all 
pathways receive a 
NAAT test 
All patients that test positive 
for a NAAT test or Microscopy 
receive Azithromycin 
Figure 1: Flow diagram showing the test and treatment pathway  
Note: NAAT-nucleic acid amplification test for Chlamydia trachomatis & Neisseria gonorrhoeae 
A proportion of patients 
go to the GP, and the 
remainder to GUM 
Al l  patients that go to GP 
receive NAAT only 
100% Symptomatic and 100% of 
asymptomatic men receive microscopy 
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Initially, a patient can be either infected or non-infected with M. genitalium and either 
symptomatic or asymptomatic. The patient may attend either a general practice (GP) or a GUM 
clinic for testing. For those patients that attend a GP setting, all patients (asymptomatic and 
symptomatic) are tested for chlamydia and gonorrhoea using nucleic acid amplification test 
(NAAT) but none are offered microscopy. From the GP setting a proportion of the patients are 
then referred to a GUM clinic for further investigation and management, for example those 
who are symptomatic or have more complex sexual health needs. 
In contrast, in the GUM setting the diagnostic pathway varies depending on which strategy is 
being considered and whether the patient presents with symptoms or not. )RU WKH µCurrent 
Recommended Practice¶ strategy, microscopy is not offered to asymptomatic patients and these 
patients receive a NAAT test for chlamydia and gonorrhoea only. All asymptomatic patients 
in all locations in WKH µ&XUUHQW Recommended 3UDFWLFH¶ scenario receive a NAAT chlamyd ia 
and gonorrhoea only. In the 5% Microscopy and µ0LFURVFRS\¶ VFHQDULRs, 5% and 100% 
of male patients respectively at GUM clinics receive urethral smear microscopy. During the 
course of the consultation all symptomatic patients in a GUM setting receive partner 
notification and condoms with the aim of identifying individuals for whom testing and 
treatment may be appropriate. The testing pathways considered in this study are shown in 
Figure 1. 
In this analysis, treatment can be deemed either a success or failure. Successful treatment 
indicates that a patient is no longer infected with M. genitalium and cannot transmit infect ion 
to their sexual partners. Treatment failure indicates that there has been a failure of the drug 
treatment to clear M. genitalium. Female patients who fail treatment or who are not treated can 
develop PID, a proportion of which cases are treated. Untreated PID cases may go on to 
experience symptomatic PID, infertility, or experience an ectopic pregnancy.  
Model assumptions and parameterisation  
This cost-effectiveness analysis was parameterised through secondary sources which are 
described below. It was necessary to make some pragmatic clarifying assumptions in order to 
carry out the analysis, these are described in the Appendix.  
The model parameters used in this analysis are shown in Table 1.  
Parameter Value (range) Reference 
Proportion of times HIV test 
delivered alongside a NAAT 
test in a GUM setting 
83% (range=0.71-0.97) (7) 
Proportion of times syphilis 
tests delivered alongside a 
NAAT test in a GUM setting 
84% (range=0.72-0.97) (7) 
Proportion PID cases that give 
rise to ectopic pregnancy 
(99/1309) 7.6% (6.4-8.8%) (8, 9) Based on number trying to 
conceive after laparoscopy 
diagnosed PID case. Range 
calculated from a beta 
distribution taking values at 5% 
and 95% parameterised using 
method of moments (10) 
Proportion PID cases that give 
rise to infertility 
18% (15-21%) (8, 11) range calculated from a 
beta distribution taking values 
at 5% and 95% assuming 
standard error = mean/10 (10) 
Proportion of PID cases that are 
symptomatic 
56% (30%-89%) Value here from Posterior-
mean of infectious disease 
model 
Delay from PID to infertility / 
ectopic pregnancy manifest 
5 years (1-15years) Expert opinion ± study team 
Table 1: Model parameters used in economic evaluation 
 
Resource use and costs  
The cost of partner notification was adjusted to 2014/15 prices using the pay and price index 
for Hospital & Community Health Services. Unit staff costs were obtained from Unit Costs of 
Health & Social Care (2015) (12). The unit costs of each resource used in this economic 
evaluation are described in the Appendix.  
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Outcomes 
The main outcome measure for this evaluation is the additional cost incurred per case of PID 
averted. The second outcome measure is the additional cost incurred per major outcome averted 
(MOA), where a major outcome is defined as a case of symptomatic PID, case of ectopic 
pregnancy, or a case of infertility. All major outcomes are reported for completeness. The 
results presented here use the incremental cost-effectiveness ratio (ICER), which is the 
difference in costs between two options divided by the difference in their effects (which are 
the outcome measures described above). 
Analysis 
The base case scenario uses the mean results of 215 parameter sets from the dynamic 
transmission model and applies resource costs to obtain the baseline deterministic results for 
each of the three testing scenarios. These deterministic results from the TDM are shown in the 
Appendix along with details of the sensitivity analysis. 
Results 
All results presented here are shown for a time horizon of 20 years with discounting unless 
otherwise stated. In all cases the costs are presented to the nearest thousand, and the outcomes 
to the nearest hundred. ICER values were calculated using the unrounded cost and outcome 










No Microscopy £1,244,736,000 111,800 37,600 23,300 10,000 4,200 
5% Microscopy £1,249,986,000 111,500 37,500 23,200 10,000 4,200 
100% Microscopy £1,350,369,000 105,300 35,600 21,800 9,700 4,100 
Table 2: Baseline results for the three strategies for cases of PID and all the major outcomes 
considered in this study 
*where major outcomes are symptomatic PID, infertility or ectopic pregnancy 
Outcomes 
As shown in Table 2, providing microscopy to 5% of asymptomatic men in a GUM setting has 
a positive impact on cases of PID. That is, the number of PID cases is lower for 5% Microscopy 
compared to No Microscopy. Likewise 5% Microscopy coverage also has a positive impact on 
reducing the number of major outcomes. In the case of the 100% Microscopy scenario, this has 
a greater impact on reducing cases of PID and major outcomes compared to either 5% or No 
Microscopy.  
Costs 
When only considering costs, it can be seen that the cost of 5% Microscopy coverage is greater 
than No Microscopy, while 100% Microscopy coverage is the most costly approach. This 
indicates that any savings that might have been made as a result of a reduction in major 
outcomes are insufficient to make 5% Microscopy or 100% Microscopy cost saving. 
  
Incremental Results  







No Microscopy £1,244,736,000 111,800  37,600  
5% Microscopy £1,249,986,000 111,500 £15,700 37,500 £49,900 
100% Microscopy £1,350,369,000 105,300 £16,300 35,600 £51,900 
Table 3: Incremental cost per case of PID averted and cost per major outcome averted 
For the outcome of a case of PID averted the ICER values are shown in Table 3. It can be seen 
that 5% Microscopy is more effective than no microscopy and has an ICER of £15,700, 
meaning that an investment of £15,700 is required to avert one case of PID. For the outcome 
of MOA it can again be seen (Table 3) that 5% Microscopy is more effective than no 
microscopy, but in this case an investment of £49,900 is required to avert one major outcome. 
In the case of 100% Microscopy, an investment of £16,300 is required to avert one case of PID, 
and £51,900 to avert one major outcome compared to 5% Microscopy. 
Sensitivity Analysis 




This economic evaluation utilized the output from a transmission dynamic model (TDM) to 
estimate whether providing limited microscopy coverage to asymptomatic men to test for 
NCNGU at a limited number of GUM services (as was the case at the time of the last nationa l 
audit of practice (1)) is a cost-effective option compared to the recommended current practice 
of its complete withdrawal.  
This economic analysis was based on a principal outcome of cases of PID averted, and a 
secondary outcome of major outcome averted (MOA) (symptomatic PID, infertility, or ectopic 
pregnancy). The results at baseline indicate that performing urethral smear microscopy for 
approximately 5% of asymptomatic men attending GUM has an incremental cost of £15,700 
per case of PID averted compared to no microscopy, meaning that this strategy invests 
approximately £15,700 to avoid one additional case of PID compared to a strategy of no routine 
microscopy screening where only symptomatic men are tested. Similarly 5% Microscopy 
coverage requires approximately £49,900 to avert one major outcome compared to a strategy 
of no routine microscopy screening where only symptomatic men are tested. Hypothetically, if 
recommended current practice were expanded to performing urethral smear microscopy for 
100% of asymptomatic men attending GUM then this would have an additional cost of £16,300 
per additional case of PID averted, and an additional £51,900 to avert an additional case of 
MOA compared to 5% Microscopy. These results also help to show that while conducting 
microscopy for 5% of asymptomatic men at GUM locations will avert PID and other major 
outcomes, at a population level it costs more to undertake the microscopy and associated patient 
management than it does to manage the adverse effects of not preventing the sequelae in a 
limited number of patients.  
Across all the sensitivity analysis undertaken, 5% microscopy coverage was never found to be 
cost saving but was always found to have a positive impact on reducing cases of PID and major 
adverse outcomes. Varying the outputs from the TDM provided a range of values for the 
outcomes in this study. For case of PID averted the ICER values ranged from £9,600-£39,100, 
while for case of MOA the ICER values ranged from £30,500-£124,400. By varying the time 
horizon of the analysis it was found that shorter time horizons made the intervention less cost-
effective.  
 Strengths & Weaknesses of Study 
This study has utilised the output from a well parameterised dynamic model that describes the 
transmission of M. genitalium in the population of males and females in England aged 16-30 
years old. Uncertainty in this model has been considered through the use of multiple parameter 
sets, while the results from this economic evaluation have been subject to extensive sensitivity 
analysis. Inevitably this has led to the range of plausible values being obtained from the 
economic model being quite wide, although this does help to give confidence to the validity of 
the conclusions that might be drawn from this model. 
In this analysis only NCNGU due to M. genitalium has been considered in the analysis, and its 
scope has not been extended to other causes. There are some causes which are innocuous 
conditions that are not tested for, such as adenovirus and these do not cause reproductive 
sequelae in women. Consequently had these non-serious causes been taken into account, then 
it is very likely that the testing strategies would have been even less cost-effective than has 
been shown here. 
A weakness of this study is the inability to conduct joint probabilistic sensitivity analysis (PSA) 
for both the economic parameters and the parameters utilized in the transmission dyna mic 
model. Although it was possible to conduct PSA for just the economic parameters while 
maintaining that output from the TDM at constant values, the results describing the probability 
of a strategy being below a specific acceptable threshold would be meaningless. 
Comparisons with existing studies 
To our knowledge this is the first economic analysis related to NCNGU in any setting, and thus 
comparisons with the results from similar economic studies are impossible. 
Meaning of study 
It is suggested that UK decision makers are unlikely to fund an intervention if it has an ICER 
value of £30,000 / quality adjusted life year (QALY) or more (13). However, as this study 
analysed outcomes in terms of cases of PID and major outcomes averted, there are no accepted 
threshold values which can be used to assess whether providing limited microscopy coverage 
to asymptomatic men is acceptable or not. It is therefore necessary to link the results here to 
the acceptance threshold values for the QALY in order to draw conclusions from this economic 
analysis.  
Taking mean values from the transmission dynamic model, the ICER for a case of PID averted 
and MOA were £15,700 and £49,900 respectively for 5% microscopy compared to no 
microscopy. Using the outcome of case of PID averted as an example, and taking into 
consideration the maximum acceptance threshold of £30,000 / QALY used by the National 
Institute of Healthcare and Care Excellence (NICE) in England, for this ICER to be deemed 
cost-effective based on current accepted thresholds, a case of PID averted would have to result 
in a gain of 0.53 of a QALY. Alternatively, the implication is that having PID would have to 
be equivalent to losing more than 6 months of perfect health. Likewise for MOA this would 
have to be more than 1.67 QALYs, meaning that having a major outcome would have to be 
equivalent to losing more than 18 months of perfect health.  
Current evidence suggests that these outcomes are not valued so extremely. Smith (14) in a 
primary study based on a time trade off approach, asked respondents with a previous history 
of PID to value alternative conditions. The mean valuations for long term health states 
associated with PID were: ectopic pregnancy 0.79 (SD=0.34); pelvic pain 0.69 (SD=0.37); 
Infertility 0.76 (SD=0.34). These values suggest that the mean QALY gain to avert a case of 
pelvic pain (the state with the reported greatest negative impact on QoL) that lasted one year 
would be 0.31 QALYs. However as noted above for the results described here, for 5% 
microscopy coverage to be cost effective, a MOA must lead to a gain of more than 1 QALY, 
suggesting that current practice is far from being cost-effective.  
Given the comparisons described above, it can therefore be concluded that recommended 
practice of reserving urethral microscopy for symptomatic men is a cost-effective strategy and 
reintroducing ad-hoc testing for asymptomatic men in GUM locations is unlikely to be cost-
effective. Considering the results at baseline in this study, if ad-hoc microscopy testing for 
asymptomatic men were reintroduced into GUM locations then this would lead to over 
£5,000,000 (discounted) in costs over a 20 year period, which could then be better spent 
expanding testing and treatment regimens for different diseases which are more cost-effective.  
Unanswered questions and future research 
One of the major issues related to any testing and diagnosis strategy is the impact of the testing 
pathway on patients. Patients may suffer from anxiety while waiting for the result of a test, or 
may incur societal costs as a result of having to take time off work to attend for testing. There 
are also issues specific to the context of sexually transmitted infections where patients may be 
worried about the stigma of attending for testing and the difficulties surrounding partner 
notification for NCNGU. In the testing and diagnosis context, future work should focus on 
these issues, in order to better quantify their impact on patients with the goal of including the 
impact of these issues in economic studies such as this in order to better describe the true impact 
of the complete testing pathway on patients. 
 
Key Messages 
x Current clinical recommendations for the UK are that urethral microscopy should not 
be offered to asymptomatic men attending genitourinary medicine clinics for diagnosis 
of NCNGU 
x Offering Microscopy at very low level of coverage where a small number of GUM 
services in England routinely offered asymptomatic men urethral microscopy for 
NCNGU is not cost-effective and wastes resources which could be put to better use 
elsewhere 
x Complete withdrawal of microscopy testing for asymptomatic men in a GUM setting 
could save over £5,000,000 (discounted) over a 20 year period 
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